Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma

Figures & data

Table 1 Clinical Characteristics of the Study Population

Variables	Numbers
Gender (%)
Male	5 (50)
Female	5 (50)
Age, years (%)
≤ 50	2 (50)
≥ 50	8 (50)
ECOG PS (%)
0–1	7 (50)
2	3 (50)
Clinical stage (%)
IVA	1 (50)
IVB	9 (50)
Pathologic types (%)
Adenocarcinoma	8 (50)
None	2 (50)
Treatment line (%)
First line	1 (50)
Second line	7 (50)
Further line	2 (50)

Figure 1 A progression-free survival curve for advanced ICC patients who received apatinib treatment.

Table 2 The Toxicities of Apatinib Treatment

Adverse Events	Grades			Total n (%)
	1	2	3–4
Fatigue	2	0	0	2 (20)
Hypertension	0	2	0	2 (20)
Hand-foot skin reaction	1	0	0	1 (10)
Proteinuria	1	2	0	3 (30)
Emesis	0	1	0	1 (10)